Skip to main content

Advertisement

SpringerLink
Log in

Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women

  • Original Article
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objectives

The aim of this study was to evaluate the effects of hormone replacement therapy (HRT) on carbohydrate and lipid metabolisms and cardiovascular risk parameters in healthy postmenopausal women.

Methods

Forty women receiving and 38 women not receiving HRT were included and baseline and sixth month blood pressure, weight, body mass index, waist/hip ratio, blood lipid profile, inflammatory markers (homocysteine, C-reactive protein (CRP) and fibrinogen), hemoglobin A1c (HbA1c) and insulin, and oral glucose tolerance test (OGTT) results were evaluated.

Results

The mean age was 52.6 ± 4.9 and 52.2 ± 5.0 years in the HRT and Control Groups, respectively. Whereas there was no change in the Controls, the weight, waist/hip ratio, and BMI increased and diastolic blood pressure decreased in the HRT patients. LDL-c, VLDL-c and lipoprotein (a) levels were significantly higher in the HRT Group in the sixth month; however, total cholesterol and LDL-c increased in the Controls but VLDL-c and lipoprotein (a) did not. CRP and homocysteine significantly increased and fibrinogen decreased, whereas in the Control Group no significant change was detected. A significant improvement in HbA1c and OGTT was found in both the groups, whereas a significant reduction was measured only in the HRT Group.

Conclusions

In response to 6 months of HRT, there was an increase in weight, BMI, and waist/hip ratio as known cardiovascular risk factors, but no significant impact on lipid profile and glucose metabolism could have been clearly demonstrated. A mixed effect profile of HRT on the state of inflammation (increase in CRP and homocysteine, decrease in fibrinogen) was observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stramba-Badiale M (2009) Postmenopausal hormone therapy and the risk of cardiovascular disease. J Cardiovasc Med (Hagerstown) 10(4):303–309

    Google Scholar 

  2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  CAS  PubMed  Google Scholar 

  3. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605–613

    Article  CAS  PubMed  Google Scholar 

  4. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, HERS Research Group (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:49–57

    Article  PubMed  Google Scholar 

  5. Zegura B, Keber I, Sebestjen M, Koenig W (2003) Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 168:123–129

    Article  CAS  PubMed  Google Scholar 

  6. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99:237–242

    CAS  PubMed  Google Scholar 

  7. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843

    Article  CAS  PubMed  Google Scholar 

  8. Christodoulakos GE, Panoulis CPC, Lambrinoudaki IV, Dendrinos SG, Rizos DA, Creatsas GC (2004) Effect of hormone replacement therapy and tibolone on serum total homocysteine levels in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 112:74–77

    Article  CAS  PubMed  Google Scholar 

  9. Li C, Samsioe G, Borgfeldt C, Bendahl PO, Wilawan K, Aberg A (2003) Low-dose hormone therapy and carbohydrate metabolism. Fertil Steril 79:550–555

    Article  PubMed  Google Scholar 

  10. Friedewald WT, Levy RI, Friedrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifugate. Clin Chem 18:499–502

    CAS  PubMed  Google Scholar 

  11. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Writing Group for the PEPI Trial. JAMA 273:199–208

    Google Scholar 

  12. Cooper BC, Burger NZ, Toth MJ, Cushman M, Sites CK (2007) Insulin resistance with hormone replacement therapy: associations with markers of inflammation and adiposity. Am J Obstet Gynecol 196(2):123–127

    Article  CAS  PubMed  Google Scholar 

  13. Kimmerle R, Heinemann L, Heise T, Bender R, Weyer C, Hirschberger S, Berger M (1999) Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women. Menopause 6:36–42

    Article  CAS  PubMed  Google Scholar 

  14. Vehkavaara S, Westerbacka J, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Yki-Jarvinen H (2000) Effect of estrogen replacement therapy on insulin sensitivity of glucose metabolism and preresistance and resistance vessel function in healthy postmenopausal women. J Clin Endocrinol Metab 85:4663–4670

    Article  CAS  PubMed  Google Scholar 

  15. Villa P, Sagnella F, Perri C, Suriano R, Costantini B, Macri F, Ricciardi L, Lanzone A (2008) Low and standard-estrogen dosage in oral therapy: dose dependent effects on insulin and lipid metabolism in healthy postmenopausal women. Climacteric 11:498–508

    Article  CAS  PubMed  Google Scholar 

  16. The Expert Committee on the diagnosis and classification of diabetes mellitus (2003) Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26:3160–3167

    Google Scholar 

  17. Naftolin F, Taylor HS, Karas R, Brinton E, Newman I, Clarkson TB, Mendelsohn M, Lobo RA, Judelson DR, Nachtigall LE, Heward CB, Hecht H, Jaff MR, Harman SM, Women’s Health Initiative (2004) The Women’s Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 81:1498–1501

    Article  PubMed  Google Scholar 

  18. Sare GM, Gray LJ, Bath PM (2008) Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 29:2031–2041

    Article  PubMed  Google Scholar 

  19. Farag NH, Barshop BA, Mills PJ (2003) Effects of estrogen and psychological stress on plasma homocysteine levels. Fertil Steril 79:256–260

    Article  PubMed  Google Scholar 

  20. Bayrak A, Aldemir DA, Bayrak T, Corakci A, Dursun P (2006) The effects of hormone replacement therapy on the levels of serum lipids, apoprotein A1, apoprotein B and lipoprotein (a) in Turkish postmenopausal women. Arch Gynecol Obstet 274:289–296

    Article  CAS  PubMed  Google Scholar 

  21. Godsland IF (2001) Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 75:898–915

    Article  CAS  PubMed  Google Scholar 

  22. Perry W, Wiseman RA (2002) Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: effect on lipids, coagulation factors, hematology and biochemistry. Maturitas 42:157–164

    Article  CAS  PubMed  Google Scholar 

  23. Prelevic GM, Kwong P, Byrne DJ, Jagroop IA, Ginsburg J, Mikhailidis DP (2002) A cross-sectional study of the effects of hormone replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women. Fertil Steril 77:945–951

    Article  PubMed  Google Scholar 

  24. Kernohan AF, Sattar N, Hilditch T, Cleland SJ, Small M, Lumsden MA, Connell JM, Petrie JR (2007) Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. Clin Endocrinol 66(1):27–34

    CAS  Google Scholar 

  25. Gram J, Bladbjerg EM, Moller L, Sjol A, Jespersen J (2000) Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study. J Intern Med 247:205–212

    Article  CAS  PubMed  Google Scholar 

  26. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98:731–733

    CAS  PubMed  Google Scholar 

  27. Ylikorkala O, Evio S, Valimaki M, Tiitinen A (2003) Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-binding globulin in osteoporotic women. Fertil Steril 80:541–545

    Article  PubMed  Google Scholar 

  28. Ridker PM, Manson JE, Buring JE, Shih J, Matias M, Hennekens CH (1999) Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 281:1817–1821

    Article  CAS  PubMed  Google Scholar 

  29. Evio S, Tiitinen A, Turpeinen U, Ylikorkala O (2000) Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil Steril 74:1080–1083

    Article  CAS  PubMed  Google Scholar 

  30. Bruschi F, Pino DD, Fiore V, Parazzini F, Di Pace R, Cesane BM, Melotti D, Crosignani PG (2004) Effect of oral or transdermal hormone replacement therapy on homocysteine levels; a randomized clinical trial. Maturitas 48:33–38

    Article  CAS  PubMed  Google Scholar 

  31. Yilmazer M, Fenkci V, Fenkci S, Sonmezer M, Aktepe O, Altindis M, Kurtay G (2003) Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. Maturitas 46:245–253

    Article  CAS  PubMed  Google Scholar 

  32. Norris LA, Joyce M, O’Keeffe N, Sheppard BL, Bonnar J (2002) Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy. Maturitas 43:125–133

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Bilim University, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey

    Banu Bingol

  2. Department of Obstetrics and Gynecology, Maltepe University, Istanbul, Turkey

    Ziya Gunenc

  3. Department of Endocrinology, Bilim University, Avrupa Florence Nightingale Hospital, Istanbul, Turkey

    Murat Yilmaz

  4. Department of Obstetrics and Gynecology, Gazi University, Ankara, Turkey

    Aydan Biri, Bülent Tiras & Haldun Güner

Authors
  1. Banu Bingol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ziya Gunenc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Murat Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aydan Biri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bülent Tiras
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haldun Güner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Banu Bingol.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bingol, B., Gunenc, Z., Yilmaz, M. et al. Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women. Arch Gynecol Obstet 281, 857–864 (2010). https://doi.org/10.1007/s00404-009-1169-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-009-1169-y

Keywords

Search

Navigation